Combination of clinical characteristics and transrectal ultrasound-guided biopsy to predict lobes without significant cancer: application in patient selection for hemiablative focal therapy

Jin-Woo Jung¹, Byung Ki Lee¹, Won Suk Choi², Yong Hyun Park¹, Sangchul Lee¹,³, Seong Jin Jeong¹,³, Sang Eun Lee¹,³, Seok-Soo Byun¹,³

¹Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea
²Choi Won Suk Urology Clinic, Yongin, Korea
³Department of Urology, Seoul National University College of Medicine, Seoul, Korea

Purpose: A major limitation of performing hemiablative focal therapy (FT) for prostate cancer (PCa) is the possibility of accompanying significant cancer in the contralateral side of the prostate that is missed on prostate biopsy. We attempted to verify whether clinical and biopsy-related parameters can be used to predict the absence of significant cancer in the prostate lobe.

Methods: We assumed that hemiablative FT could be performed in patients with low-risk PCa, with unilateral tumors as assessed by transrectal ultrasound-guided biopsy. We evaluated 214 patients who had undergone radical prostatectomy (RP) and fulfilled the eligibility criteria. Seemingly preserved lobes, defined by the absence of cancer on biopsy, were classified as lobes with no cancer (LNC), lobes with insignificant cancer (LIC), and lobes with significant cancer (LSC) according to RP pathology. Cases with an estimated tumor volume of < 0.5 mL, a Gleason score of < 7, and organ confinement without Gleason pattern 4 were classified as LIC. Univariate and multivariate logistic regression analyses were performed to identify predictors for LSC. Predictive accuracies of the multivariate models were assessed using receiver operating characteristic curve-derived areas under the curve.

Results: Of 214 evaluated lobes, 45 (21.0%), 62 (29.0%), and 107 (50.0%) were classified as LNC, LIC, and LSC, respectively. Among the clinical and biopsy-related parameters, prostate-specific antigen density and prostate volume were identified as significant predictors for LSC in univariate regression analysis. However, multivariate analysis did not identify an independent predictor. Predictive accuracies of the multivariate models did not exceed 70.4%.

Conclusions: Conventional parameters have limited value in predicting LSC in patients who are candidates for hemiablative FT.

Keywords: Prostatic neoplasms, Tissue preservation, Patient selection

INTRODUCTION

In the era of prostate-specific antigen (PSA) measurement, prostate cancer (PCa) is increasingly being detected at an early stage and with a low risk, but the management of localized PCa remains controversial because early detection and conventional treatment do not seem to be able to reduce mortality and improve the quality of life [1,2]. Radical whole gland surgery or radiation therapy can result in substantial side effects. Urinary incontinence (5%–20%), erectile dysfunc-
function (30%-50%), and bowel toxicity (5%-10%) are typical complications of radical treatment [3,4]. For the treatment of low-risk PCa, active surveillance (AS) can be a treatment option; however, cancer-related anxiety is the major drawback to this course [5].

Focal therapy (FT) is receiving increasing attention as a middle ground between AS and radical treatment, to selectively eradicate localized PCa while preserving uninvolved structures to minimize treatment-related side effects [6-8]. Hemiablative FT, which involves ablation of the entire half of the prostate associated with cancer, might be the most feasible and straightforward form of FT [9]. Hemiablative FT can be used even in cases of bilateral PCa with a significant unilateral lesion and an insignificant lesion on the contralateral side. This is because the index lesion determines the clinical outcome, and the secondary lesions are unlikely to result in disease progression [10,11]. Some authors claim that FT targeting an index lesion alone may be sufficient when supplemented with AS for the untreated insignificant lesions [7,12,13].

For the performance of appropriate hemiablative FT, the side contralateral to the ablated lobe is supposed to contain no significant lesions. We attempted to identify conventional prostate biopsy and clinical characteristics that could predict the presence of significant cancer in the seemingly preserved lobe, contralateral to the lobe with the index lesion.

MATERIALS AND METHODS

Between January 2008 and October 2012, 1,140 men underwent RP for PCa at Seoul National University Bundang Hospital, Seongnam, Korea. Clinical data for these men had previously been entered into a prospectively maintained computerized database. After obtaining Institutional Review Board approval, we reviewed the data on 832 of these patients who had undergone prostate biopsy using a single technique at our institution. After the measurement of prostate volume, all patients underwent transrectal ultrasound (TRUS)-guided 12-core biopsy of the prostate. The prostate was biopsied at both sides near the base, midgland, and apex, with at least six biopsy specimens obtained per side. In cases of lesions suspicious for PCa based on TRUS, one or two additional targeted biopsy specimens were obtained. Low-risk patients (clinical stage ≤ T2a; Gleason score [GS] ≤ 6; and PSA level < 10 ng/mL) with a unilateral tumor as proven by TRUS biopsy were selected as candidates for hemiablative FT. Of the 832 patients who underwent RP using a single technique, 310 had low-risk PCa, and of these 310 patients, 214 had unilateral tumors as proven by biopsy.

All biopsy and RP specimens were analyzed by a single genitourinary pathologist (G.C.), and RP specimens were processed according to the Stanford Protocol [14]. Tumor volume was measured by multiplying the X and Y diameters and tumor depth, which was calculated according to the thicknesses of subsequent sections that showed the presence of tumor, as previously described and validated [15,16]. We classified the preserved lobes as lobes with no cancer (LNC), lobes with insignificant cancer (LIC), and lobes with significant cancer (LSC) according to the RP pathologic reports. Using the Epstein criteria [17], cases with a total tumor volume accounting for all foci of < 0.5 mL, a GS of < 7, and organ confinement without Gleason pattern 4 on one side were classified as LIC. If the index tumor was located between both lobes, we considered it to be present on the preserved side. To evaluate the possibility of preserving one lobe of the prostate by performing hemiablative FT, LNC or LIC was considered suitable for hemiablative FT.

1. Statistical analyses

Categorical variables are presented as frequencies and percentages, and continuous variables are presented as mean ± standard deviation. Age, PSA level, percentage of positive cores among the total biopsy cores (% of positive cores), and the maximum percentage of tumor length in positive cores (% of tumor length) were entered into the models as continuous variables. Clinical T stage, PSA density (PSAD), and GS were treated as dichotomous variables. Logistic regression models were conducted for univariate and multivariate analyses to identify significant predictors of LSC. Receiver operating characteristic (ROC) curve-derived areas under the curve (AUCs) were calculated for each parameter in the multivariate model for estimating LSC. All statistical analyses were performed using IBM SPSS ver. 20.0 (IBM Co., Armonk, NY, USA). A two-tailed P-value of < 0.05 was considered significant for all analyses.

RESULTS

The clinical and biopsy-related characteristics of patients are shown in Table 1. The mean patient age was 65.14 ± 6.82 years. cT1b, cT1c, and cT2a disease were identified in 1 (0.5%), 174 (81.3%), and 39 patients (18.2%), respectively. The mean PSA level was 5.56 ± 1.20 ng/mL, and the PSAD was 0.16 ± 0.08 ng·mL⁻¹·cm⁻³. The mean prostate volume was 38.36 ± 13.84 cm³. Further, 159 (74.3%), 32 (15.0%), and 22 patients (10.3%) underwent 12-, 13-, and 14-core biopsy, respectively, and 126 patients (58.9%) showed only one positive core on TRUS-
guided biopsy. The percentage of positive cores was 14.34% ± 10.01%. The maximum core and tumor lengths were 16.80 ± 7.16 and 2.90 ± 2.35 mm, respectively, and the percentage of tumor length was 17.95% ± 14.93%.

Of the 214 preserved lobes, 45 (21.0%) were found to have no cancer and cancer was detected in the RP specimens of the other 169 lobes. The GS was ≤ 3+3 in 87 lobes (40.7%) and ≥ 3+4 in 82 lobes (38.8%). Nine lobes (4.2%) showed extraprostatic extension, and 67 lobes (31.3%) had a tumor volume of ≥ 0.5 cm³. Accordingly, 45 (21.0%), 73 (34.1%), and 96 lobes (44.9%) were classified as LNC, LIC, and LSC, respectively (Table 2).

We examined the associations between clinical and biopsy-related variables and the lobe category. Of the clinical and biopsy-related parameters, GS was excluded from regression analysis because all patients showed a GS of 6 except for 1 who had GS of 5 based on the analysis of TRUS-guided biopsy specimens. Univariate logistic regression analysis showed that PSAD and prostate volume were significant predictors of LSC, but multivariate analysis did not identify any parameter as an independent predictor (Table 3).

To estimate the predictive accuracy of each parameter for LSC, ROC curve-derived AUCs were calculated. AUCs for all parameters were less than 64%, the largest being for PSAD, at 63.9%. The predictive accuracy of a multivariate model, including age, PSAD, prostate volume, and the other variables mentioned here, for predicting LSC was 70.4% (Table 3). The predictive accuracies of other multivariate models incorporating age and PSAD with various combinations of the other variables were < 70%.

**DISCUSSION**

Recent studies including ours showed that 17%–22% of men undergoing RP have PCa confined to one side of the gland, although the populations in these studies were different [9,18,19]. In our cohort of 214 patients with low-risk PCa, 107 (55.1%) did not have significant cancer in the seemingly preserved side. Thus, a substantial proportion of men with

---

**Table 1.** Clinical and biopsy-related characteristics of the patients

| Characteristic         | Value          |
|------------------------|----------------|
| Age (yr)               | 65.14 ± 6.82   |
| Body mass index (kg/m²)| 24.35 ± 2.56   |
| Clinical state         |                |
| ≤ T1c                  | 175 (81.8)     |
| T2a                    | 39 (18.2)      |
| PSA level (ng/mL)      | 5.56 ± 1.20    |
| PSAD (ng · ml⁻¹ · cm⁻³)| 0.16 ± 0.08    |
| Prostate volume (cm³)  | 38.36 ± 13.84  |
| Gleason score          |                |
| 5                      | 1 (0.5)        |
| 6                      | 213 (99.5)     |
| % of positive core     | 14.34 ± 10.01  |
| % of tumor length      | 17.95 ± 14.93  |

Values are presented as mean ± standard deviation or number (%). PSA, prostate-specific antigen; PSAD, PSA density.

---

**Table 2.** Pathologic features of preserved lobes as assessed on the basis of the radical prostatectomy permanent report

| Variable                        | Preserved prostate lobes |
|---------------------------------|---------------------------|
| Gleason score                   |                           |
| ≤ 3+3                           | 87 (40.7)                 |
| ≥ 3+4                           | 82 (38.3)                 |
| Extraprostatic extension        | 9 (4.2)                   |
| Tumor volume ≥ 0.5 cm³          | 67 (31.3)                 |
| Lobe category                   |                           |
| LNC                             | 45 (21.0)                 |
| LIC                             | 73 (34.1)                 |
| LSC                             | 96 (44.9)                 |

Values are presented number (%). LNC, lobe with no cancer; LIC, lobe with insignificant cancer; LSC, lobe with significant cancer.

---

**Table 3.** Univariate and multivariate logistic regression analysis for the prediction of lobes with significant cancer

| Variable                        | Univariate | Multivariate |
|---------------------------------|------------|--------------|
|                                 | OR (95% CI) | P-value      | AUC (%)     | OR (95% CI) | P-value | AUC (%) |
| Age                             | 1.03 (0.99–1.07) | 0.19 | 54.3 | 1.04 (1.00–1.09) | 0.06 | 70.4 |
| Body mass index                 | 0.91 (0.82–1.01) | 0.08 | 57.2 | 0.95 (0.84–1.07) | 0.38 |
| Clinical stage (T2a vs. ≤ T1c)  | 0.48 (0.23–1.01) | 0.05 | 54.8 | 0.48 (0.22–1.04) | 0.06 |
| PSA                             | 1.09 (0.95–1.25) | 0.21 | 56.1 | 1.07 (0.86–1.34) | 0.55 |
| PSAD (≥ 0.15 vs. < 0.15)        | 3.13 (1.79–5.48) | <0.01 | 63.9 | 1.95 (0.74–5.11) | 0.18 |
| Prostate volume                 | 0.97 (0.95–0.99) | 0.03 | 63.2 | 0.97 (0.94–1.01) | 0.13 |
| % of positive core              | 1.01 (0.98–1.04) | 0.43 | 53.6 | 1.01 (0.98–1.04) | 0.63 |
| % of tumor length               | 1.00 (0.98–1.02) | 0.98 | 52.4 | 0.99 (0.97–1.02) | 0.56 |

Total

PSA, prostate-specific antigen; PSAD, PSA density; AUC, area under the curve; OR, odds ratio; CI, confidence interval.
clinically low-risk PCa can be treated with hemiablative FT. Here, we attempted to identify the clinical and biopsy-related parameters that could predict the presence of pathologically significant cancer in the lobe contralateral to the side treated with ablation. However, no independent predictors were identified in multivariate regression analysis. In addition, none of the parameters or multivariate models showed satisfactory predictive accuracies in ROC curve-derived AUC analysis.

Previous studies reported that PSA, taking more prostate biopsy cores, maximum cancer length and family history of PCa were predictor factor of tumor unilaterality based upon RP [9,18-20]. As for the prediction of pathologically insignificant or unfavourable PCa among low-grade PCa cancers, some reported that PSAD and age were correlated with insignificant PCa [21,22]. On the other hand, other authors failed to identify clinical or biopsy-related parameters predicting such pathological outcome [23,24]. There are still controversies to find predictor factor of tumor laterality and clinical significance in PCa patients with preoperative parameters. The differences of experimental group, biopsy protocol and pathologic reporting system were thought of main causes of those results.

Prebiopsy magnetic resonance imaging (MRI) has the benefit of facilitating prior detection of lesions not expected to be identified by systematic prostate biopsy. However, in a large study, Giannarini et al. [25] showed that differentiation between PCa and normal prostatic tissue, not only in the transition zone but also in the peripheral zone, is very difficult based on T2-weighed images. The conventional approach to managing cases with a high PSA level is TRUS-guided prostate biopsy followed by MRI for PCa staging. Conditions other than PCa such as postbiopsy hemorrhaging, scarring, positional and inflammatory changes, and dystrophic changes can interfere with the accuracy of MRI investigations [26,27]. Therefore, we did not include MRI parameters in our evaluations for identifying predictive factors and estimating predictive accuracies.

Matsuoka et al. [28] reported that a combination of diffusion-weighted imaging and extended prostate biopsy can efficiently be used to predict lobes without significant cancer. In their study, the negative predictive value for predicting LSC was 95.7%. However, indolent cancer was defined as organ-confined disease with a tumor volume of < 0.5 cm3 and a GS of ≤3+4 without Gleason pattern 5. Although definitions of significant cancer vary, a GS of 3+4 seems too high to accept as representative of insignificant cancer. FT represents a potential compromise between AS and radical therapy, offering advantages of the resolution of anxiety and the avoidance of urinary and sexual side effects associated with whole gland treatment [9]. The management strategy must not only meet the curative intent of treatment, but must also account for the safety of AS. Thus, strict criteria may be required in determining the clinical significance of the preserved side based on pathologic reports of RP specimens.

The current study has several limitations. First, we did not include all patients with low-risk PCa detected at our institution. Those treated with AS or radiation therapy were excluded from this study, because we were unable to obtain final pathologic reports for them. Application of FT is not limited to patients who are due to receive RP, and so our study may contain a selection bias associated with the inclusion criteria. In addition, in a hypothetical study based on a database of RP patients, we attempted to determine appropriate selection criteria for FT. However, this therapy was not administered to patients with PCa, and so we were unable to assess biochemical recurrence and cancer-specific survival, which might be more important than pathological features for selection of FT. In conclusion, among patients with low-risk PCa who had unilateral tumors based on conventional multicore (≥12) biopsy, 44.9% had pathologically determined LSC and 34.1% harbored LIC. However, no independent predictors of LSC in patients who are candidates for hemiablative FT were identified. In addition, our data showed that the clinical and biopsy-related parameters currently available have limited value in the prediction of pathologically determined LSC. Further efforts should be made to identify more accurate predictors of actual pathological characteristics and prognosis of PCa to ultimately improve the selection of candidates for hemiablative FT.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This research was financially supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012R1A1A2006392).

REFERENCES

1. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341:c4543.
2. Baade PD, Youlden DR, Cramb SM, Dunn J, Gardiner RA. Epidemiology of prostate cancer in the Asia-Pacific region. Prostate Int 2013;1:47-58.

3. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-61.

4. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148:435-48.

5. Latini DM, Hart SL, Knight SJ, Cowan JE, Ross PL, Duchane J, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 2007;178(3 Pt 1):826-31.

6. Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 2012;62:55-63.

7. Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 2007;4:632-42.

8. Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012;13:622-32.

9. Tareen B, Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS. Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort. Urology 2009;73:351-4.

10. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002;60:264-9.

11. Noguchi M, Stamey TA, McNeal JE, Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 2003;170(2 Pt 1):459-63.

12. Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int 2010;106:1607-11.

13. Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis 2011;14:46-52.

14. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.

15. Renshaw AA, Chang H, D'Amico AV. Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice. Am J Clin Pathol 1997;107:704-8.

16. Porten SP, Cooperberg MR, Carroll PR. The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int 2010;105:472-5.

17. Epstein JJ, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.

18. Tsivian M, Kimura M, Sun L, Mouraviev V, Mayes JM, Polascik TJ. Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int 2010;105:1089-92.

19. Polascik TJ, Mayes JM, Schroek FR, Sun L, Madden JE, Moul JW, et al. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer 2009;115:2104-10.

20. Park EA, Lee HJ, Kim KG, Kim SH, Lee SE, Choe GY. Prediction of pathological stages before prostatectomy in prostate cancer patients: analysis of 12 systematic prostate needle biopsy specimens. Int J Urol 2007;14:704-8.

21. Allan RW, Sanderson H, Epstein JJ. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 2003;170(2 Pt 1):370-2.

22. Thong AE, Shikanov S, Katz MH, Gofrit ON, Eggenger S, Zagaja GP, et al. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy: can we predict adverse pathological outcomes? J Urol 2008;180:2436-40.

23. D’Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score ≤7. Cancer 2000;89:1810-7.

24. Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, Boccon-Gibod LA. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol 2005;48:895-9.

25. Giannarini G, Petralia G, Thoeny HC. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 2012;61:326-40.

26. Schiebler ML, Tomaszewski JE, Bezzi M, Pollack HM, Kessel HY, Cohen EK, et al. Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and
histopathologic findings. Radiology 1989;172:131-7.

27. White S, Hricak H, Forstner R, Kurhanewicz J, Vigneron DB, Zaloudek CJ, et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 1995;195:385-90.

28. Matsuoka Y, Numao N, Saito K, Tanaka H, Kumagai J, Yoshida S, et al. Combination of diffusion-weighted magnetic resonance imaging and extended prostate biopsy predicts lobes without significant cancer: application in patient selection for hemiablative focal therapy. Eur Urol 2014;65:186-92.